Discussion  by unknown
of diabetes. These effects may be mediated by the direct
effects of insulin on the myocardium and coronary vascu-
lature or indirectly through systemic reductions in blood
glucose. Anti-angiogenic proteins, angiostatin and endosta-
tin, are downregulated with insulin treatment and appear to
play an important role in the diabetic angiogenic response.
Insulin therapy appears to be a promising strategy to im-
prove the results of growth factor or cell-based angiogenic
therapies in diabetic patients.
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Discussion
Dr Mark J. Krasna (Towson, Md). I was quite impressed with the
technical feat of this study. Can you elaborate on the three proce-
dures that you performed on each of these animals and was there
any mortality among the three groups?
Dr Boodhwani. In the past we have done more than 400
ameroid constrictor experiments in our laboratory. We found that
in a potent model of diet induced hypercholesteremia, there was
about a 10% to 20% mortality rate with the animals, but over time
the techniques have been improved and we have a much better
sense of what the model entails now. Fortunately, in this study, we
did not lose any animals.
Dr Krasna. Along the same lines, when you are doing three
procedures on each animal, was there a significant infection rate
from the first to the third, or was that also low?
Dr. Boodhwani. In the normal, nondiabetic animals (group
ND) there was virtually no infection. In the diabetic animals we
found that there was some impairment of wound healing and
breakdown of the incision. However, to emphasize, all animals
were treated with postoperative antibiotics for 5 days.
Dr Paul W. M. Fedak (Calgary, Alberta, Canada). This is a
great study. I think this model is going to be very important for
future studies in the area. My question to you is, I did not see
anything about regional or global left ventricular function. Was
that addressed in this study or will it be addressed in any future
studies? If not, what would you hypothesize would be the effects
of insulin treatment?
Dr Boodhwani. In the past we have demonstrated that circum-
flex ameroid constrictor placement leads to a reduction in perfu-
sion as well as regional wall motion abnormalities. Regional wall
motion abnormalities were not specifically studied in this model,
although we did assess global left ventricular function. We expect,
though, that improvement in perfusion would likely result in
improvement in regional wall motion as well.
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